Lv11
80 积分 2024-04-22 加入
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
5小时前
待确认
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
24天前
已完结
LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
24天前
已完结
HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance
24天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
26天前
已完结
Treatment after progression in the era of immunotherapy
26天前
已完结
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
1个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
2个月前
已完结
Exploiting the folate receptor α in oncology
3个月前
已完结
皖公网安备34019202002308
